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OBJECTIVES This study compared survival after percutaneous coronary intervention (PCI) with survival
after coronary artery bypass graft surgery (CABG) among diabetics in the Veterans Affairs
AWESOME (Angina With Extremely Serious Operative Mortality Evaluation) study
randomized trial and registry of high-risk patients.
BACKGROUND Previous studies indicate that CABG may be superior to PCI for diabetics, but no
comparisons have been made for diabetics at high risk for surgery.
METHODS Over five years (1995 to 2000), 2,431 patients with medically refractory myocardial ischemia
and at least one of five risk factors (prior CABG, myocardial infarction within seven days, left
ventricular ejection fraction 0.35, age 70 years, or an intra-aortic balloon being required
to stabilize) were identified. A total of 781 were acceptable for CABG and PCI, and 454
consented to be randomized. The 1,650 patients not acceptable for both CABG and PCI
constitute the physician-directed registry, and the 327 who were acceptable but refused to be
randomized constitute the patient-choice registry. Diabetes prevalence was 32% (144) among
randomized patients, 27% (89) in the patient-choice registry, and 32% (525) in the
physician-directed registry. The CABG and PCI survival rates were compared using
Kaplan-Meier curves and log-rank tests.
RESULTS The respective CABG and PCI 36-month survival rates for diabetic patients were 72% and 81%
for randomized patients, 85% and 89% for patient-choice registry patients, and 73% and 71% for
the physician-directed registry patients. None of the differences was statistically significant.
CONCLUSIONS We conclude that PCI is a relatively safe alternative to CABG for diabetic patients with
medically refractory unstable angina who are at high risk for CABG. (J Am Coll Cardiol
2002;40:1555–66) © 2002 by the American College of Cardiology Foundation
Randomized clinical trials comparing percutaneous coro-
nary intervention (PCI) with coronary artery bypass graft
surgery (CABG) have demonstrated comparable long-term
survival (1–11) in most patient populations, with the im-
portant exception of diabetics. The Bypass Angioplasty
Revascularization Investigation (BARI) study (12,13)
showed a significant and sustained survival benefit for
CABG at five years in treated diabetics, and similar findings
were noted in other randomized studies and large databases
(2,14). These findings are reflected in current guidelines
which favor CABG over PCI in most diabetics with two- or
three-vessel coronary artery disease (CAD) who require
revascularization (15,16). Such recommendations are not
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universally accepted because contemporary PCI, character-
ized by widespread use of stents and glycoprotein IIb/IIIa
receptor blocking drugs, is more effective in diabetics than
the balloon angioplasty techniques used in BARI.
The choice of revascularization remains uncertain. Sev-
eral studies have failed to demonstrate a survival benefit for
CABG over PCI in diabetics (3,17). Even the BARI
registry showed comparable survival for diabetics who chose
PCI over CABG (18). The choice of revascularization for
diabetic patients who are at high risk for CABG is also
uncertain. These patients might have equivalent or superior
outcomes with a less invasive PCI procedure. The recently
concluded, Angina With Extremely Serious Operative
Mortality Evaluation (AWESOME), was a randomized
clinical trial of PCI versus CABG among patients with
medically refractory ischemia who were at high risk for
CABG because of one or more of the following high-risk
factors: prior heart surgery; myocardial infarction (MI)
within seven days; left ventricular ejection fraction (LVEF)
0.35; age70 years; intra-aortic balloon being required to
stabilize (19,20). Eligible patients who were deemed by
study physicians to be suitable for both CABG and PCI
were asked to participate in the randomized trial. Eligible
patients who were acceptable to study physicians for either
CABG or PCI but who refused to be randomized were
entered into a prospective patient-choice registry. Eligible
patients who were directed by physicians not to participate
were entered into a physician-directed registry. This article
reports the outcomes of the high-risk diabetic patients in
the randomized clinical trial and the physician-directed and
patient-choice registries of the AWESOME study.
METHODS
The AWESOME was a nationwide, prospective, random-
ized clinical trial designed to compare CABG and PCI
survival for patients with medically refractory unstable
angina and at high risk of adverse outcomes with CABG.
Patients were enrolled at 16 Veterans Affairs medical
centers over a five-year period (1995 to 2000). The AWE-
SOME protocol, baseline characteristics, and survival for
the randomized patients have been previously reported
(19,20).
Screening identified 2,431 clinically eligible patients who
met the three criteria (medically refractory, unstable angina,
at least one additional high-risk factor). Medically refractory
was defined as anginal symptoms despite aspirin and/or
heparin and control of heart rate and blood pressure as
previously described (19). Unstable angina was defined as
rest angina with electrocardiographic changes or known
CAD; recurrent rest angina; or stabilized rest angina with a
subsequent positive stress test. High risk for CABG was
defined as age 70 years, one or more prior open-heart
operations, LVEF 0.35, MI within seven days, or intra-
aortic balloon pump necessary. The diagnosis of MI re-
quired hospitalization and cardiac enzyme or troponin
elevation. After coronary angiography had been reviewed by
both interventional cardiologist and surgeon, 781 (32%)
who were acceptable to both operators as candidates for
CABG or PCI were approached for informed consent, and
454 (58%) consented to a randomized choice of revascular-
ization. Randomization was stratified by age and prior heart
surgery. The 327 patients who refused random allocation
were entered into a patient-choice registry. The 1,650
patients for whom physician consensus would not allow
random assignments were entered into a physician-directed
registry. Patient data, including the presence or absence of
diabetes, were entered by the study nurses into an interactive
data management system as previously described (19).
Statistical analysis. Differences in baseline variable fre-
quencies were judged by chi-square tests. Long-term sur-
vival was measured by Kaplan-Meier survival estimates,
which were plotted. The statistical significance of global
differences between survival curves was judged by log-rank
tests. Differences between CABG and PCI 36-month
Abbreviations and Acronyms
AWESOME  Angina With Extremely Serious
Operative Mortality Evaluation
CABG  coronary artery bypass graft surgery
CAD  coronary artery disease
LVEF  left ventricular ejection fraction
MI  myocardial infarction
PCI  percutaneous coronary intervention
TIMI  Thrombolysis In Myocardial Infarction
Table 1. Baseline Characteristics of Randomized and Registry
Diabetic Patients
Baseline Random Registry
Physician-
Directed
Patient
Choice
Patients (n) 144 614 525 89
Age  70 yrs (%) 51 53 54 51
Prior PCI (%) 20 18 18 19
Prior CABG (%) 34 43* 43 39
Prior MI (%) 58 56 55 63
MI  7 days (%) 33 31 30 37
LVEF  0.35 (%) 17 20 20 19
CHF (%) 9 14 15 7
Prior stroke (%) 10 13 13 11
Hypertension (%) 79 80 80 82
Smoker (%) 28 21 20 23
Vessels
Two-vessel (%) 40 34 33 41‡
Three-vessel (%) 46 51 54 38
TIMI no flow (%) 41 55† 57 49
Statistically significant difference between random and registry: *p 0.05, †p 0.01.
Statistically significant difference between physician-directed and patient choice: ‡p
0.05.
CABG  coronary artery bypass graft surgery; CHF  congestive heart failure;
LVEF  left ventricular ejection fraction; MI  myocardial infarction; PCI 
percutaneous coronary intervention; TIMI  Thrombolysis In Myocardial Infarction
trial.
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survival were computed along with z tests of the differences.
All comparisons of randomized patients are based on
intention to treat.
RESULTS
Patients treated with either insulin or oral hypoglycemic
drugs were classified as diabetic for the purposes of this
study. Among the 144 randomized diabetic patients, 79
were assigned to CABG and 65 to PCI. Among the 525
physician-directed diabetic patients, 238 were selected for
CABG, 194 for PCI, and 93 received medical care. Among
the 89 patient-choice diabetic patients, 20 chose CABG, 65
chose PCI, and four patients chose medical care.
Table 1 presents baseline characteristics of randomized,
all registry, physician-directed, and patient-choice diabetic
patients. The randomized and registry diabetic patients have
similar baseline profiles except for prior CABG and Throm-
bolysis in Myocardial Infarction (TIMI) no flow, which
have higher rates in the registry, and the differences are
statistically significant (chi-square; p  0.05). The
physician-directed and patient-choice patients have similar
baseline profiles except for number of vessel diseases, which
has a higher rate of three-vessel disease in the physician-
directed patients and for which the difference is statistically
significant (chi-square; p  0.01).
Table 2 presents baseline characteristics of randomized,
physician-directed, and patient-choice diabetic patients as-
signed to CABG or PCI. The baseline characteristics of
diabetic patients randomized to CABG or PCI are similar,
and none of the differences is statistically significant. Both
physician-directed and patient-choice patients assigned to
CABG have significantly higher rates of older patients.
Physician-directed patients assigned to CABG have signif-
icantly higher rate of three-vessel disease and lower rates of
prior PCI, prior CABG, prior MI, and TIMI no flow
Table 2. Baseline Characteristics of Randomized and Registry Diabetic Patients by
Revascularization
Baseline
Random Physician-Directed Patient Choice
CABG
(n  79)
PCI
(n  65)
CABG
(n  238)
PCI
(n  194)
CABG
(n  20)
PCI
(n  65)
(%) (%) (%) (%) (%) (%)
Age  70 yrs 56 46 67 41† 70 43*
Prior PCI 22 19 12 28† 30 17
Prior CABG 39 28 18 64† 30 43
Prior MI 57 60 51 62† 50 66
MI  7 days 29 37 33 27 30 38
LVEF  0.35 41 42 43 42 51 45
CHF 13 5 13 18 10 6
Prior stroke 10 10 12 15 10 12
Hypertension 77 82 80 79 85 80
Smoker 30 26 21 18 23 25
Vessels
Two-vessel 35 45 33 32* 67 31*
Three-vessel 54 40 61 50 27 44
TIMI no flow 48 34 44 61* 47 51
Statistically significant difference between CABG and PCI: *p  0.05, †p  0.01.
Abbreviations as in Table 1.
Table 3. Short-Term CABG and PCI Outcomes of Diabetic Patients
Randomized Physician-Directed Patient Choice
Outcomes
CABG
(n  79)
PCI
(n  65)
CABG
(n  238)
PCI
(n  194)
CABG
(n  20)
PCI
(n  65)
Revascularized 96% 100% 96% 99% 95% 100%
Received CABG 90% 3% 96% 5% 85% 8%
Received
PCI 8% 100% 3% 98% 10% 98%
Only CABG 89% 0% 93% 2% 85% 2%
Only PCI 6% 97% 0.4% 96% 10% 92%
CABG and PCI 1% 3% 2.5% 3% 0% 6%
Survival to
30 days 92% 97% 94% 94% 85% 100%
6 months 86% 91% 87% 86% 85% 97%
CABG  coronary artery bypass graft surgery; PCI  percutaneous coronary intervention.
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relative to physician-directed patients assigned to PCI.
Patient-choice patients assigned to CABG have signifi-
cantly lower rates of three-vessel disease and show lower
rates relative to those assigned to PCI for prior CABG,
prior MI, and TIMI no flow, but the differences are not
statistically significant. The lower rate of prior CABG in
both physician-directed and in patient-choice registries was
also observed among the non-diabetic patients. This pattern
may reflect the reluctance of physicians to operate on
patients with a patent left internal mammary artery to the
left anterior descending coronary artery.
Table 3 presents short-term outcomes of randomized and
registry patients assigned to CABG or PCI. The large
majority of patients assigned to revascularization were re-
vascularized, and over 96% were revascularized as assigned
(94% assigned to CABG received CABG; 98% assigned to
PCI received PCI). Approximately 80% of the CABG
patients received left internal mammary artery (78%, 78%,
and 79% of the randomized, physician-directed, and
patient-choice, respectively); the corresponding right inter-
nal mammary artery frequencies were 3%, 2%, and 0% for
the randomized, physician-directed, and patient-choice,
respectively. The CABG and PCI survival to 30 days and to
six months did not differ significantly. Overall in-hospital
mortality in the 324 diabetic patients treated by PCI did not
differ significantly from the in-hospital mortality in the 337
diabetics treated by CABG (4% vs. 7%).
Table 4 presents 36-month CABG and PCI survival,
survival free of recurrent unstable angina, and survival free
of unstable angina or a repeated revascularization for the
randomized, physician-directed, and patient-choice diabetic
Table 4. CABG and PCI 36-Month Diabetic Patient Survival,
Survival Free of Unstable Angina, and Survival Free of Unstable
Angina or Repeat Revascularizations
Outcome CABG PCI
CABG-PCI
Difference
Standard
Error
Survival
Randomized 72% 81% 9% 9%
Physician-directed 73% 71% 2% 6%
Patient choice 85% 89% 4% 11%
Survival free of unstable
angina
Randomized 61% 61% 0% 14%
Physician-directed 62% 44% 18% 10%
Patient choice 72% 53% 19% 20%
Survival free of unstable
angina or repeat
revascularization
Randomized 54% 49% 5% 18%
Physician-directed 59% 38% 21% 12%
Patient choice 72% 46% 26% 22%
Abbreviations as in Table 3.
Figure 1. Kaplan-Meier five-year survival curves of coronary artery bypass graft surgery (CABG) (circle) and percutaneous coronary intervention (PCI)
(cross) for randomized patients.
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Figure 2. Kaplan-Meier five-year survival curves of CABG (circle) and PCI (cross) for physician-directed patients. Abbreviations as in Figure 1.
Figure 3. Kaplan-Meier five-year survival curves of CABG (circle) and PCI (cross) for the patient-choice cohort. Abbreviations as in Figure 1.
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Figure 4. Kaplan-Meier curves of CABG (circle) and PCI (cross) five-year survival free of unstable angina for randomized patients. Abbreviations as in
Figure 1.
Figure 5. Kaplan-Meier curves of CABG (circle) and PCI (cross) five-year survival free of unstable angina for physician-directed patients. Abbreviations
as in Figure 1.
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patients. The table also shows the CABG-PCI differences
and the standard errors of the differences.
Figures 1 to 3 present the five-year Kaplan-Meier survival
curves and a global log-rank test of CABG versus PCI
survival differences over the five-year period for randomized
patients and the two registry cohorts. The CABG and PCI
number of patients (N) for each time period are shown at
the bottom of the plots. None of the three log-rank tests is
statistically significant.
Figures 4 to 6 present the five-year Kaplan-Meier survival
free of unstable angina and a global log-rank test of CABG
versus PCI survival differences over the five-year period for
randomized patients and the two registry cohorts. The
CABG and PCI number of patients (N) for each time
period are shown at the bottom of the plots. The log-rank
test for the physician-directed cohort is statistically signifi-
cant (p  0.0001).
Figures 7 to 9 present the five-year Kaplan-Meier survival
free of unstable angina and repeat revascularizations and a
global log-rank test of CABG versus PCI survival differ-
ences over the five-year period for randomized patients and
the two registry cohorts. The CABG and PCI number of
patients (N) for each time period are shown at the bottom
of the plots. The log-rank test for the physician-directed
cohort is statistically significant (p  0.0001).
Table 5 shows the percent of diabetic patients allocated to
CABG overall and for selected high-risk subsets. The
percent allocated to PCI is the complement of the percent
allocated to CABG. For example, the 55% of all physician-
directed diabetic patients allocated to CABG implies that
the remaining 45% were allocated to PCI. Table 5 shows
that the choice of CABG differs greatly between the two
registry cohorts (55% in physician-directed vs. 24% in
patient-choice). The difference between these two cohorts is
large and statistically significant (p  0.01). Table 5 also
shows how the presence of other high-risk factors influences
the choice of revascularization within the two registry
cohorts. Within the physician-directed cohort, 77% of the
age 70 patients were allocated to CABG versus 44% for
the younger patients. This large and statistically significant
difference suggests that physicians favor CABG over PCI
for older patients. Physicians appear to favor PCI over
CABG for patients with prior CABG or prior PCI. The
other high-risk factors do not appear to change preferences
in the physician-directed cohort. Among the patient-choice
cohort, older patients are more likely to receive CABG than
younger diabetic patients (33% vs. 14%), but both age
groups favor PCI over CABG. The other high-risk factors
do not appear to change patient preference for PCI in the
patient-choice cohort.
Figure 6. Kaplan-Meier curves of CABG (circle) and PCI (cross) five-year survival free of unstable angina for the patient-choice cohort. Abbreviations
as in Figure 1.
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DISCUSSION
The outcome of diabetic patients in the AWESOME
randomized trial and registry suggests that PCI is a reason-
able option for diabetics with two- or three-vessel CAD and
medically refractory angina who are at risk for adverse
outcomes with CABG because of prior CABG, recent MI,
poor left ventricular function, age 70, or instability neces-
sitating intra-aortic balloon pump (19–21). There is no
survival advantage with CABG, but there is less recurrent
unstable angina and the need for repeat revascularization
with surgery.
Diabetes is associated with adverse outcomes for both
CABG and PCI (17). Operative mortality for CABG is
higher for diabetics than for non-diabetics (22–29), and
diabetes is an important risk factor for the development of
serious postoperative complications, including renal failure
and sternal wound infection (30–33). Complications of
CABG in diabetics result in a significant clinical and
economic burden (34–38), underscoring the importance of
alternative therapies for diabetic patients, especially for
diabetic patients at high risk for CABG. Unfortunately,
mortality for PCI is also higher for diabetics than for
non-diabetics (39–45), and restenosis rates are significantly
higher for diabetics than for non-diabetics (with restenosis
rates for balloon angioplasty approaching 50%). Previously
reported data do not provide support for either CABG or
PCI as an initial strategy for diabetics with multivessel
CAD who are at high risk for adverse outcomes with
CABG.
There are important differences between the AWE-
SOME study and earlier studies such as BARI and the
Emory Angioplasty Surgery Trial (EAST) which showed a
benefit for CABG in diabetics. The AWESOME study
enrolled patients at higher risk for adverse outcomes with
CABG than were enrolled in BARI and EAST. For
example, patients with prior CABG were excluded from
BARI and EAST. This may have had an important influ-
ence on the outcome of the study. A recent analysis of
mortality in the BARI study showed that approximately
50% of the survival benefit for CABG in the diabetic
patients could be explained by a lower mortality during
Q-wave MI. In contrast, there was no difference in the
incidence of Q-wave MI between diabetics undergoing
CABG or PCI (46). Although Q-wave MI was relatively
rare in diabetics enrolled in the study (8% incidence in
five-year follow-up), the mortality rate strikingly was sev-
enfold higher in diabetics randomized to angioplasty com-
pared with CABG (46). Importantly, this survival benefit
Figure 7. Kaplan-Meier curves of CABG (circle) and PCI (cross) five-year survival free of unstable angina and repeat revascularizations for randomized
patients. Abbreviations as in Figure 1.
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Figure 8. Kaplan-Meier curves of CABG (circle) and PCI (cross) five-year survival free of unstable angina and repeat revascularizations for
physician-directed patients. Abbreviations as in Figure 1.
Figure 9. Kaplan-Meier curves of CABG (circle) and PCI (cross) five-year survival free of unstable angina and repeat revascularizations for the
patient-choice cohort. Abbreviations as in Figure 1.
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for CABG was almost entirely limited to patients who
received at least one internal mammary artery graft (46).
These findings have therapeutic implications. Firstly, dia-
betic patients with prior CABG (especially those with
durable patent internal mammary grafts) might be expected
to retain a survival benefit from their first operation and so
conceivably would have less benefit from a re-operation
compared with the benefit of angioplasty. This hypothesis
was not tested in BARI because all patients with prior
CABG were excluded from the trial. Secondly, the outcome
of MI in diabetics has improved in recent years (even in very
high-risk groups) as a result of intensive therapy with
angiotensin-converting enzyme inhibitors (47), insulin (48),
and early revascularization (49). These advances in therapy
of MI would be expected to narrow the difference in survival
between diabetics with CAD treated by an initial strategy of
CABG or PCI.
Another major cause of the difference between the
outcomes in the BARI study and the outcomes that can be
expected today with PCI in diabetics is the widespread use
of stents and glycoprotein IIb/IIIa receptor blockers in
contemporary practice. The BARI study enrolled patients
between 1988 and 1991, and balloon angioplasty was the
only procedure performed in patients randomized to the
PCI arm of BARI. It has now been recognized that stents
and glycoprotein IIb/IIIa receptor blockers reduce restenosis
and long-term mortality in diabetics with multi-vessel
disease. Diabetic patients were a prospectively defined
subset in the multicenter Evaluation of Platelet IIb/IIIa
Inhibitor for Stenting Trial (EPISTENT) in which patients
were randomized to stent-placebo, stent-abciximab, or
balloon-abciximab (50). The combined six-month rate of
death, MI, or target-vessel revascularization occurred in
25.2% of stent-placebo, 23.4% of balloon-abciximab, and
only 13.0% of stent-abciximab patients in that study (p 
0.005). The one-year mortality rate for diabetics in
EPISTENT was 4.1% for stent-placebo and 1.2% for
stent-abciximab patients (p  0.11). In the AWESOME
study, overall use of stents was 54% and overall use of
glycoprotein IIB/IIIa antagonists was 11% (20,21).
The outcome of diabetic patients randomized between
April 1997 and June 1998 to either CABG or PCI with
stenting in the Arterial Revascularization Therapy Study
(ARTS) trial has been recently published (50). In that study,
event-free one-year survival in diabetics treated with stent-
ing was 63.4% compared with 84.4% with CABG (p 
0.001). In contrast, there was no difference in outcomes at
one year among non-diabetics. Importantly, ARTS ex-
cluded all patients with prior CABG, MI within one week,
ejection fraction 30%, and prior stroke. Thus the findings
of ARTS cannot be extrapolated to the high-risk population
enrolled in AWESOME. Furthermore, the long-term out-
come of diabetics enrolled in ARTS is still unknown.
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